Crónicas de autores

Edimar Bocchi *

Autor invitado por SIIC

O trabalho é um avanço no tratamento de insuficiência cardíaca em pacientes caquéticos e dependentes de dobutamina


O uso de HG em pacientes com insuficiência cardíaca descompensada e caquexia determinou estabilidade clínica sem a necessidade de drogas inotrópicas permitindo introdução de drogas não previamente toleradas.

*Edimar Bocchi
describe para SIIC los aspectos relevantes de su trabajo
International Journal of Cardiology,
110(3):313-317 Jun, 2006

Esta revista, clasificada por SIIC Data Bases, integra el acervo bibliográfico
de la Biblioteca Biomédica (BB) SIIC.

Institución principal de la investigación
*Heart Failure Clinics of the Clinical Cardiology Department, Heart Institute of the São Paulo Univer, São Paulo, Brasil
Imprimir nota
Referencias bibliográficas
Graves E, Gillium B. 1994 Summary: National Hospital Discharge Survey: Advance Data. Atlanta, Ga: National Center for Health Statistics; 1996:17.
Dies F, Krell M, Whitlow P. Intermittent, ambulatory dobutamine infusion in severe chronic cardiac failure. Br J Clin Pract 1986; 40:37-39.
Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA 2002; 287:628-40.
VMAC Investigators. Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure. JAMA 2002; 287:1531-40.
Follath F, Cleland JGF, Hust H, et al. for the steering committee and investigators of the levosimendan infusion versus dobutamine (LIDO) study. Lancet 2002; 360:196-202.
Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997; 349:1050.
Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997; 96(2):526-534.
Anker SD, Volterrami P, Pflaum CD et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol 2001; 38:443-52.
Frustaci A, Perrone GA, Geniloni NR, et al. Reversible dilated cardiomyopathy due to growth hormone deficiency. Am J Cardiol 1992; 97:503:11.
Volterrani M, Desenzani P, Lorusso R, et al. Haemodynamic effects of growth hormone in congestive heart failure. Lancet 1997; 349:1067:1068.
Khan AS, Sane DC, Wannenburg T, et al. Growth hormone, insulin-like growth factor-1 and the aging cardiovascular system. Cardiovasc Res 2002; 54:25-35.
Cittadini A, Isgaard J, Monti MG, et al. Growth hormone prolongs survival in experimental heart failure. J Am Coll Cardiol 2003; 41:2154-63.
Sacca L. Growth hormone therapy for heart failure: swimming against the stream. J Cardiol Fail 1999; 5:269-75.
O´Driscoll JG, Green DJ, Ireland M, et al. Treatment of end-stage cardiac failure with growth hormone. Lancet 1997; 349:1068.
Giustina A, Volerrani M, Manelli F, et al. Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure. Am Heart J 1999; 137(6):1035-1043.
Napoli R, Guardasole V, Matarazzo M, et al. Growth hormone corrects vascular dysfunction in patients with chronic heart failure. J Am Coll Cardiol 2002; 39:90-95.
Fazio S, Sabatini D, Capaldo B, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996; 334:810-4.
Osterziel KJ, Strohm O, Schuler J, et al. Randomized, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998; 351:1233-7.
Isgaard J, Bergin C, Caidahi K, et al. A placebo controlled study of growth hormone in patients with congestive heart failure. Eur Heart J 1998; 19:1704-11.
Takala J, Ruokonen E, Webster N, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341(11):785-792.
Duncan B, Moyna NM, Heller GV, et al. A 24-hour comparison of serum growht hormone concentration in patients with heart failure versus healthy controls. Pharmacotherapy 2003; 23:147-52.
Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD, et al. Hormonal profile in patients with congestive heart failure. Int J Cardiol 2003; 87:179-83.
Cicoira M, Kalra PR, Anker SD. Growth hormone resistance in chronic heart failure and its therapeutic implications. J Card Fail 2003; 9:219-26.
Dalla-Libera L, Ravara B, Volterrani M et al. Beneficial effects of GH/IGF-1 on skeletal muscle atrophy and function in experimental heart failure. Am J Physiol Cell Physiol 2004; 286:C138-44.
Perrot A, Ranke MB, Dietz R, Osterzief. Growth hormone treatment in dilated cardiomyopathy. J Card Surg 2001; 16:127-31.
Tajima M, Weinberg EO, Bartunek J, et al. Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure. Circulation 1999; 99:127-134.
Hambrecht R, Schulze P, Gielen S, Linke A et al. Reduction of insulin-like growth factor-l expression in skeletal muscle of noncachectic patients with chronic heart failure. J Am Coll Cardiol 2002; 39:1175-81.
Houck WV, Pan LC, Kribbs SB, et al. Effects of growth hormone supplementation on left ventricular morphology and myocyte function. Circulation 1999; 100:2003-9.
King M, Gay D, Pan L, et al. Treatment with a growth hormone secretagogue in a model of developing heart failure. Effects on ventricular and myocyte function. Circulation 2001; 103(2):308-313.
Niebauer J, Palum CD, Clark AL, et al. Deficient insulin-growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J Am Coll Cardiol 1998; 32:393-7.
Sharma R, Anker S. From tissue wasting to cachexia: changes in peripheral blood flow and skeletal musculature. Eur Heart J Suppl 2002; 4:D12-17.
Wu Y, Tewari M, Cui S, et al. Activation of the insulin-like growth factor-1 receptor inhibits tumor necrosis factor -induced cell death. J Cell Physiol 1996; 168:499-509.
Gonzales-Juanatey JR, Pineiro R, Iglesias MJ, et al. GH prevents apoptosis in cardiomyocytes cultured in vitro through a calcineurin-dependent mechanism. J Endocrinol 2004; 180:325-35.
Sverrisdottir YB, Elam M, Herlitz H, et al. Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency. J Clin Endocrinol Metab 1998; 83:1881-5.
Pagel I, Langenickel T, Philipp S Cardiac and renal effects of growth hormone in volume overload-induced heart failure. Role of NO. Hypertension 2002; 39:57-62.
Karoor V, Malbon CC. Insulin-like growth factor receptor-1 stimulates phosphorylation of the adrenergic receptor in vivo on sites distinct from those phosphorylated in response to insulin. J Biol Chem 1996; 271:29347-52.
Jin H, Yang R, Lu H, et al. Effects of early treatment with growth hormones on infarct size, survival, and cardiac gene expression after acute myocardial infarction. Growth Horm IGF Res 2002; 12:208-15.
Adamopoulos S, Parissis JT, Georgiadis M, et al. Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy. Am Heart J 2002; 44:359-64.
Adamopoulos S, Parissis JT, Paraskevaidis I, et al. Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy. Eur Heart J 2003; 24:2186-96.
Sacca L, Napoli R, Cittadini A. Growth hormone, acromegaly, and heart failure: an intricate triangulation. Clin Endocrinol 2003; 59:660-71.
Otros artículos de Edimar Bocchi

Bocchi EA, Ahualli L, Amuchastegui M, Boullon F, Cerutti B, Colque R, Fernandez D, Fiorelli A, Olaya P, Vulcado N, Perrone SV. Recommendations for use of everolimus after heart transplantation: results from a Latin-American consensus meeting. Transplant Proc 2006; 38(3):937-42.
Bacal F, Pires PV, Moreira LF, Silva CP, Filho JR, Costa UM, Rosario-Neto MA, Avila VM, Cruz FD, Guimaraes GV, Issa VS, Ferreira SA, Stolf N, Ramires JA, Bocchi E. Normalization of right ventricular performance and remodeling evaluated by magnetic resonance imaging at late follow-up of heart transplantation: relationship between function, exercise capacity and pulmonary vascular resistance. J Heart Lung Transplant 2005; 24(12):2031-6.
Chizzola PR, Goncalves de Freitas HF, Marinho NV, Mansur JA, Meneghetti JC, Bocchi EA. The effect of beta-adrenergic receptor antagonism in cardiac sympathetic neuronal remodeling in patients with heart failure. Int J Cardiol 2006; 106(1):29-34.
Fiorelli AI, Stolf NA, Honorato R, Bocchi E, Bacal F, Uip D, Strabelli T, Issa V, Amato VA, Fiorelli LR, Oliveira SA. Later evolution after cardiac transplantation in Chagas' disease. Transplant Proc 2005; 37(6):2793-8.
Bocchi E, Moura L, Guimaraes G, Conceicao Souza GE, Ramires JA. Beneficial effects of high doses of growth hormone in the introduction and optimization of medical treatment in decompensated congestive heart failure. Int J Cardiol 2006; 110(3):313-7.
Rodrigues AC, Frimm CC, Bacal F, Andreolli V, Tsutsui JM, Bocchi EA, Mathias W Jr, Lage SG. Coronary flow reserve impairment predicts cardiac events in heart transplant patients with preserved left ventricular function. Int J Cardiol 2005; 103(2):201-6.
Mocelin AO, Issa VS, Bacal F, Guimaraes GV, Cunha E, Bocchi EA. The influence of aetiology on inflammatory and neurohumoral activation in patients with severe heart failure: a prospective study comparing Chagas' heart disease and idiopathic dilated cardiomyopathy. Eur J Heart Fail 2005; 7(5):869-73.
Bacal F, Silva CP, Bocchi EA, Pires PV, Moreira LF, Issa VS, Moreira SA, Das Dores Cruz F, Strabelli T, Stolf NA, Ramires JA. Mychophenolate mofetil increased Chagas' disease reactivation in heart transplanted patients: comparison between two different protocols. Am J Transplant 2005; 5(8):2017-21.
Curiati JA, Bocchi E, Freire JO, Arantes AC, Braga M, Garcia Y, Guimaraes G, Fo WJ. Meditation reduces sympathetic activation and improves the quality of life in elderly patients with optimally treated heart failure: a prospective randomized study. J Altern Complement Med 2005; 11(3):465-72.

Para comunicarse con Edimar Bocchi mencionar a SIIC como referencia:

Autor invitado
25 de julio, 2006
Descripción aprobada
5 de octubre, 2006
Reedición siicsalud
7 de junio, 2021

Acerca del trabajo completo

Edimar Bocchi1, Ligia Moura2, Guilherme Guimarães3, Germano Conceição4, Jose Ramires5
1, Heart Failure Clinics of the Clinical Cardiology Department, Heart Institute of the São Paulo Univer, São Paulo, Brasil

Acceso a la fuente original
International Journal of Cardiology

El artículo se relaciona estrictamente con las especialidades de siicsalud
El artículo se conecta secundariamente con las especialidades